References
- Norris LA, Joyce M, O’Keeffe N, Sheppard BL, Bonnar J. Haemostatic risk factors in healthy postmenopausal women taking hormone replacement therapy. Maturitas 2002;43:125–133.
- Farquhar C, Marjoribanks J, Lethaby A, Suckling JA, Lamberts Q. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2009;CD004143.
- Junge W, El-Samalouti V, Gerlinger C, Schaefers M. Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate. Eur J Obstet Gynecol Reprod Biol 2009;147:195–200.
- Sandset PM, Høibraaten E, Eilertsen AL, Dahm A. Mechanisms of thrombosis related to hormone therapy. Thromb Res 2009;123 Suppl 2:S70–S73.
- Miller VM, Jayachandran M, Heit JA, Owen WG. Estrogen therapy and thrombotic risk. Pharmacol Ther 2006;111:792–807.
- Peruga J, Kopff A, Krzemińska-Pakuła M. Hormone replacement therapy. The cardiologist’s point of view. Przegląd Menopauzalny 2007;1:3–7.
- Sumino H, Ichikawa S, Sawada Y, Sakamoto H, Kumakura H, Takayama Y, Sakamaki T, Kurabayashi M. Effects of hormone replacement therapy on blood coagulation and fibrinolysis in hypertensive and normotensive postmenopausal women. Thromb Res 2005;115:359–366.
- Norris LA, Brosnan J, Bonnar J, Conard J, Kluft C, Hellgren M. Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone. Thromb Haemost 2008;100:253–260.
- Simomcini T, Mannella P, Genazzani AR. When hormone therapy sneaks under your nose. Menopause 2008;15:215–216.
- Callejon DR, Franceschini SA, Montes MB, Toloi MR. Hormone replacement therapy and hemostasis: effects in Brazilian postmenopausal women. Maturitas 2005;52:249–255.
- Scarabin PY, Oger E, Plu-Bureau G; EStrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428–432.
- Koh SCL, Dramusc V, Ratnam S. The effects of long-term hormone-replacement therapy on coagulation, fibrynolysis and inhibitors in postmenopausal women. Int J Gynecol Obst 1998;62:279–285.
- Kostka B, Para J, Sikora J. A multiparameter test of clot formation and fibrinolysis for in-vitro drug screening. Blood Coagul Fibrinolysis 2007;18:611–618.
- Lau A, Berry LR, Mitchell LG, Chan AK. Effect of substrate and fibrin polymerization inhibitor on determination of plasma thrombin generation in vitro. Thromb Res 2007;119:667–677.
- Wohl RC, Summaria L, Robbins KC. Kinetics of activation of human plasminogen by different activator species at pH 7.4 and 37 degrees C. J Biol Chem 1980;255:2005–2013.
- Peverill RE. Hormone therapy and venous thromboembolism. Best Pract Res Clin Endocrinol Metab 2003;17:149–164.
- Brosnan JF, Sheppard BL, Norris LA. Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration? Thromb Haemost 2007;97:558–565.
- Stevenson JC, Oladipo A, Manassiev N, Whitehead MI, Guilford S, Proudler AJ. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br J Haematol 2004;124:802–808.
- Koh SCL, McCarthy TG, Dramusic V, Castelo T, Ratnam SS. Randomized comparative cross-over study between two hormonal preparations for hormone-replacement therapy; Their effects on the coagulation, fibrinolysis and inhibitor mechanisms. Singapore J Obstet Gynaecol 1994;25:298–307.
- Caine YG, Bauer KA, Barzegar S, ten Cate H, Sacks FM, Walsh BW, Schiff I, Rosenberg RD. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992;68:392–395.
- De Lignieres B, Basdevant A, Thomas G, Thalabard JC, Mercier-Bodard C, Conard J, Guyene TT, et al. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 1986;62:536–541.
- Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol Haemost Thromb 2003;33:375–381.
- Boffa MB, Wang W, Bajzar L, Nesheim ME. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem 1998;273:2127–2135.
- Rosendaal FR, Van Hylckama Vlieg A, Tanis BC, Helmerhorst FM. Estrogens, progestogens and thrombosis. J Thromb Haemost 2003;1:1371–1380.